All In Biotech

Drug Trial Radar · NCT05066997

A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)

A Phase 2/3 Double-Masked, Randomized, 2 Stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema

Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Title says "pivotal". Randomized with 552 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

552

Actual

Start

Oct 19, 2021

Primary completion

Apr 10, 2026

Study completion Apr 10, 2026

Sponsor

Lead sponsor
OculisIndustry
Sponsor type
Industry
First posted
Oct 4, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of OCS- 01 as compared to Vehicle in participants with Diabetic Macular Edema (DME).

Conditions

  • Diabetic Macular Edema

Interventions

  • Dexamethasone ophthalmic suspension (OCS-01)Drug

    Stage 1: Participants will be dosed with one eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 6 weeks (maintenance phase). Stage 2: Participants will be dosed with one eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase).

  • VehicleDrug

    Stage 1: Participants will be dosed with one eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 6 weeks (maintenance phase). Stage 2: Participant will be dosed with one eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change in BCVA (Best Corrected Visual Acuity)Time frame: Week 52

Locations

52 sites in 4 countries. Site status is shown where the registry gives one.

  • Arizona Retina and Vitreous Consultants

    Phoenix, Arizona

  • Phoenix Retina Associates

    Phoenix, Arizona

  • Retina Partners of Northwest Arkansas

    Springdale, Arkansas

  • Retina-Vitreous Associates Medical Group

    Beverly Hills, California

  • The Retina Partners

    Encino, California

  • Retinal Consultants Medical Group

    Modesto, California

  • California Eye Specialists Medical Group

    Pasadena, California

  • California Eye Specialists Medical Group

    Redlands, California

  • Retina Consultants of Southern California

    Redlands, California

  • California Retina Consultants

    Santa Maria, California

  • Retina Group Of New England

    Waterford, Connecticut

  • Rand Eye Institute

    Deerfield Beach, Florida

  • Florida Retina Institute

    Jacksonville, Florida

  • MedEye Associates

    Miami, Florida

  • Florida Retina Institute

    Orlando, Florida

  • Retina Care Specialists

    Palm Beach Gardens, Florida

  • East Florida Eye Institute

    Stuart, Florida

  • Southeast Retina Center

    Augusta, Georgia

  • Retina Associates

    Elmhurst, Illinois

  • University Retina

    Lemont, Illinois

  • Midwest Eye Institute

    Carmel, Indiana

  • Cumberland Valley Retina Consultants

    Hagerstown, Maryland

  • Retina Consultants of Minnesota

    Saint Louis Park, Minnesota

  • The Retina Institute

    St Louis, Missouri

  • Retina-Vitreous Surgeons of Central New York

    Liverpool, New York

  • North Carolina Retina Associates

    Wake Forest, North Carolina

  • Velocity (Meridian) Clinical Research

    Cincinnati, Ohio

  • Verum Research LLC

    Eugene, Oregon

  • Vision Research Solutions in Philadelphia

    Philadelphia, Pennsylvania

  • Retina Consultants of Charleston

    Beaufort, South Carolina

  • Charleston Neuroscience Institute

    Ladson, South Carolina

  • Black Hills Regional Eye Institute

    Rapid City, South Dakota

  • Retina Research Institute of Texas

    Abilene, Texas

  • Retina Consultants of Austin/Austin Research Center for Retina

    Austin, Texas

  • Texas Retina Associates

    Dallas, Texas

  • Retina Center of Texas

    Grapevine, Texas

  • Valley Retina Institute PA d.b.a. Gulf Coast Eye Institute

    McAllen, Texas

  • Tyler Retina Consultants

    Tyler, Texas

  • Strategic Clinical Research Group

    Willow Park, Texas

  • Piedmont Eye Center

    Lynchburg, Virginia

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.